NKY(SZ:300109)2019-05-15 16:00Financial Performance - The company reported a profit distribution plan to distribute a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 217,936,025 shares[11]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[18]. - The company reported a total revenue of 13,918,437 from March 7, 2015, to March 6, 2025, focusing on technology research and development of new products[50]. - The company reported a total revenue of 9,236.83 million RMB, with a net profit of 2,522.25 million RMB, reflecting a profit margin of approximately 27.3%[109]. - The company achieved operating revenue of ¥698,283,178.03, a year-on-year increase of 42.92%[66]. - The company reported a net profit attributable to shareholders for 2018 was ¥89,546,168.64, a decrease of 3.53% from ¥92,823,189.13 in 2017[26]. - The company reported a cash dividend payout ratio of 24.34% of its net profit for 2018, compared to 18.29% for 2017[148]. - The company reported a year-on-year increase in revenue, reflecting successful implementation of its growth strategies and market expansion efforts[54]. Market Expansion and Strategy - The company has been actively expanding its overseas market presence, which may expose it to cultural and exchange rate risks[11]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[19]. - The company is focused on expanding its market through new product development and strategic partnerships in the healthcare industry[50]. - The company aims to strengthen its competitive edge in the healthcare sector through strategic acquisitions and collaborations[128]. - The company is actively pursuing partnerships with leading healthcare institutions to enhance its diagnostic capabilities and expand its service reach[19]. - The company is exploring strategic acquisitions to enhance its technological capabilities and market reach, aiming for a more competitive position in the healthcare sector[54]. Research and Development - The company has invested in new technologies and product development, focusing on PVP series products and their applications[5]. - The company reported a 40% increase in investment in R&D, totaling 200 million RMB, to support innovation and product development initiatives[18]. - The company has established a technology R&D center and a polymer application research institute to enhance product innovation and development[35]. - The company has filed for 10 invention patents in 2018, reflecting its commitment to innovation and technology advancement in the medical field[71]. - The company is focusing on the development of new technologies, including a high-throughput sequencing platform and a software for m6A analysis, with completion rates of 70% and 65% respectively[92]. - The company has established a comprehensive sales management system, which may improve operational efficiency and customer engagement[57]. Environmental and Safety Management - The company has completed the "coal-to-gas" project and the recycled water reuse project, enhancing its environmental management efforts[7]. - The company has increased its efforts in environmental protection, responding to stricter regulations since the implementation of the new Environmental Protection Law in 2015[7]. - The company has implemented a "dual prevention mechanism" for safety management, with no major safety incidents reported during the reporting period[5]. - The company has established a comprehensive safety production management system to mitigate risks associated with its chemical products[5]. - The company has established a low-boiling solvent closed-loop recovery system and implemented a clean production model to enhance environmental protection measures[71]. Talent and Governance - The company emphasizes the importance of retaining and attracting high-quality technical talent to maintain its innovation and development capabilities[9]. - The company is committed to improving its internal control and governance in response to the challenges posed by overseas investments[11]. - The company has focused on internal talent development, emphasizing a diverse management team and a comprehensive talent promotion and training system[70]. - The company is committed to enhancing its market competitiveness in the healthcare sector through strategic acquisitions and technological advancements[139]. Product Development and Innovation - New product development includes the launch of a cutting-edge DNA sequencing technology, expected to reduce costs by 30% and improve processing speed by 50%[20]. - The introduction of a new quality management system is expected to improve operational efficiency by 20% and ensure compliance with international standards[20]. - The company has developed new medical consultation services and remote medical services, reflecting its adaptation to market demands[50]. - The company has established over 30 precision medicine studios in collaboration with industry experts to expand its precision medical services[128]. - The company has developed a total of 33 software products, focusing on genomic analysis and disease diagnostics, indicating a strong emphasis on R&D[59]. Financial Management and Investments - The company has made contributions to Qianhai Fund, impacting its cash reserves during the reporting period[39]. - The company has increased its long-term deferred expenses due to rising renovation costs, reflecting ongoing investments in infrastructure[39]. - The company has cumulatively used CNY 173.10 million of the raised funds, with CNY 3.66 million spent on cervical cancer screening projects[101]. - The company has not reported any significant achievements or awards related to its social responsibility efforts[195]. - The company is currently undergoing a major asset restructuring to acquire BioVision, which specializes in life science research reagents, enhancing its competitive position in the precision medicine sector[139]. Compliance and Commitments - The actual controller, shareholders, and related parties fulfilled their commitments during the reporting period[150]. - The company has commitments regarding share transfer restrictions, with 60.5% of shares unlocking after 48 months[151]. - The company is in normal compliance with its share lock-up commitments, with various percentages unlocking at specified intervals[152]. - The company has not encountered any major changes in project feasibility during the reporting period[108]. - The company has not reported any unused raised funds, which are all stored in a dedicated account[105].